BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35543472)

  • 1. Role of fluorodeoxyglucose-positron emission tomography in predicting the pathological response and prognosis after neoadjuvant chemoradiotherapy for locally advanced non-small-cell lung cancer.
    Tanahashi M; Suzuki E; Yoshii N; Watanabe T; Tsuchida H; Yobita S; Iguchi K; Uchiyama S; Nakamura M
    Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35543472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography.
    Shiraishi K; Nomori H; Ohba Y; Kaji M; Mori T; Shibata H; Oya N; Sasaki J
    Ann Thorac Cardiovasc Surg; 2010 Dec; 16(6):394-400. PubMed ID: 21263419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation.
    Lee J; Choi JY; Lim SW; Ahn MJ; Park K; Zo JI; Shim YM; Oh D; Sun JM
    Eur J Cardiothorac Surg; 2020 Nov; 58(5):1019-1026. PubMed ID: 32920638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
    Cheng Y; Chen ZY; Huang JJ; Shao D
    Eur Radiol; 2023 Oct; 33(10):6625-6635. PubMed ID: 37515634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of
    Zhuang F; Haoran E; Huang J; Wu J; Xu L; Zhang L; Li Q; Li C; Zhao Y; Yang M; Ma M; She Y; Chen H; Luo Q; Zhao D; Chen C
    Lung Cancer; 2023 Apr; 178():20-27. PubMed ID: 36764154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor angiogenesis at baseline identified by
    Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
    J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy.
    Kim N; Kim JS; Geol Lee C
    PLoS One; 2020; 15(7):e0236350. PubMed ID: 32687531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.
    Bahce I; Vos CG; Dickhoff C; Hartemink KJ; Dahele M; Smit EF; Boellaard R; Hoekstra OS; Thunnissen E
    Lung Cancer; 2014 Aug; 85(2):205-12. PubMed ID: 24854401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer.
    Cerfolio RJ; Bryant AS; Winokur TS; Ohja B; Bartolucci AA
    Ann Thorac Surg; 2004 Dec; 78(6):1903-9; discussion 1909. PubMed ID: 15560998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of
    Lee JW; Seo KH; Kim ES; Lee SM
    Eur Radiol; 2017 May; 27(5):1912-1921. PubMed ID: 27590191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
    Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
    Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
    Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
    Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
    Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
    J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
    Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
    [No Abstract]   [Full Text] [Related]  

  • 20. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.